Boardroom Alpha
Boardroom Alpha
PFX · Current Report (Form 8-K) · Filed March 20, 2026

Phenixfin Corp — Current Report (Form 8-K)

Form
8-K
Filed
March 20, 2026
Period
Mar 20, 2026
Ticker
PFX
Accession
0001213900-26-032335
Boardroom Alpha · Filing insights

Stockholders approved two director elections, ratified KPMG, and endorsed executive compensation advisory vote at annual meeting.

About Phenixfin Corp
Market cap
$87M
1Y TSR
−14.9%
3Y TSR
+7.1%
Board grade
C
Sector
Financial Services
CEO
David A Lorber
Last annual meeting: Mar 20, 2026 · View full Phenixfin Corp profile →

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): March 20, 2026

 

PHENIXFIN CORPORATION

(Exact name of registrant as specified in its charter)

 

Delaware   814-00818   27-4576073
(State or other jurisdiction
of incorporation or organization)
  (Commission file number)   (I.R.S. employer
identification no.)

 

445 Park Avenue, 10th Floor, New York, NY   10022
(Address of principal executive offices)   (Zip code)

 

Registrant’s telephone number, including area code: (212) 859-0390

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of exchange on which registered
Common Stock, par value $0.001 per share   PFX   The NASDAQ Global Market
5.25% Notes due 2028   PFXNZ   The NASDAQ Global Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

Item 5.07 SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.

 

On March 20, 2026, PhenixFIN Corporation (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”). During this meeting, the Company’s stockholders were asked to consider and vote upon three proposals: (1) to elect two directors of the Company, to serve for a term of three years, or until his or her successor is duly elected and qualified; (2) to ratify the selection of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending September 30, 2026; and (3) to provide an advisory vote on executive compensation.

 

Stockholders of record at the close of business on January 23, 2026 were entitled to vote at the Annual Meeting. As of January 23, 2026, there were 2,000,560 shares of common stock outstanding and entitled to vote. A quorum consisting of 1,424,752 shares of common stock of the Company were present or represented by proxy at the Annual Meeting.

 

The final voting results for each of the proposals submitted to a vote of stockholders at the Annual Meeting are set forth below. Proposals 1, 2, and 3 were approved by the requisite vote.

 

Proposal 1: Election of directors.

 

Nominee    For    Withheld 
Karen Hirtler-Garvey     1,037,446     39,153 
Lowell W. Robinson     968,775     107,824 

 

Broker Non-Votes: 348,153

 

Proposal 2: Ratification of the selection of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending September 30, 2026.

 

For   Against   Abstain 
 1,412,772    11,416    564 

 

Broker Non-Votes: 0

 

Proposal 3: Advisory vote on executive compensation.

 

For   Against   Abstain 
 956,003    29,980    90,616 

 

Broker Non-Votes: 348,153

 

- 1 - 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, PhenixFIN Corporation has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

DATE: March 20, 2026 PHENIXFIN CORPORATION
     
  /s/ David Lorber
  Name: David Lorber
  Title: Chief Executive Officer

 

- 2 - 

 

From this filing to the file

Every SEC filing, parsed structured.

Boardroom Alpha indexes every 8-K, 10-K, 10-Q, and proxy back to 2000 — vote tabulations, comp tables, red flags, insider transactions, all queryable the day they hit EDGAR.

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Phenixfin Corp (PFX)

Reference

Frequently asked questions

When did Phenixfin Corp file this 8-K?
Phenixfin Corp (PFX) filed this Current Report (Form 8-K) with the SEC on March 20, 2026. The accession number assigned by EDGAR is 0001213900-26-032335.
What does an 8-K disclose?
Form 8-K is the SEC's current-report form, used to disclose material events between periodic reports (10-K / 10-Q). Triggers include CEO/CFO departures, acquisitions, bankruptcies, earnings releases, auditor changes, changes in fiscal year, and amendments to corporate governance. Each 8-K is keyed to one or more Item numbers (1.01 through 9.01).
What is the key takeaway from this filing?
Stockholders approved two director elections, ratified KPMG, and endorsed executive compensation advisory vote at annual meeting. This is Boardroom Alpha's one-line summary of the current report; see the full filing text above for the formal disclosure.
What Item codes does an 8-K cover?
An 8-K's Item codes (1.01 through 9.01) specify what kind of event is being disclosed — e.g. Item 1.01 for entering a material agreement, Item 5.02 for departure/election of directors and executive officers, Item 8.01 for other events. The Item codes for this 8-K appear in the filing text above.
Where can I find Phenixfin Corp's prior current reports on EDGAR?
The SEC EDGAR browser lists every 8-K Phenixfin Corp has filed under CIK 1490349, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer